Emails Show Allergan Asked Goldman To "Take off The Gloves" In Valeant FightMark Melin
Recently unearthed emails, letters to regulators and legal strategy documents sent by Allergan, Inc. (NYSE:AGN) executives and their consortium of paid consultants paint a picture of a company engaged in a multiple-prong attack to damage the reputation of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX), sink its stock price and fight a regulatory battle.
Allergan's attempt to manipulate the stock price of Valeant Pharmaceuticals
Perhaps most interesting about the 30 some documents reviewed by ValueWalk, many marked “confidential” or “highly confidential . . .
This content is exclusively for paying members.
If you are subscribed and having an account error please clear cache and cookies if that does not work email [email protected] or click Chat.